Centrexion eyes $70M-$80M in IPO with big plans for PhIII non-opioid painkiller
With both of Centrexion’s Phase III registration studies in full swing, Jeff Kindler is angling for as much as $80 million in IPO cash to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
